Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alnylam Pharmaceuticals is conducting a global observational study titled ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis). The study aims to describe the epidemiological and clinical characteristics of ATTR amyloidosis, assess the safety and effectiveness of treatments like patisiran and vutrisiran, and observe disease progression in pre-symptomatic carriers of a TTR variant.
The study focuses on two main interventions: patisiran and vutrisiran, both designed to manage ATTR amyloidosis by targeting the transthyretin protein to reduce amyloid deposits in tissues.
This observational study uses a cohort model with a prospective time perspective. Participants include diagnosed patients and pre-symptomatic carriers, with no specific allocation or masking involved, focusing on real-world clinical management.
The study began on November 23, 2020, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 15, 2025, indicating ongoing recruitment and data collection.
This study update could positively influence Alnylam’s stock performance by reinforcing investor confidence in its pipeline, particularly if the treatments prove effective. It also positions Alnylam competitively in the ATTR amyloidosis treatment market, where advancements are closely watched by investors.
The study is ongoing, with further details available on the ClinicalTrials portal.